Biocryst Pharmaceuticals Stock
Price
Target price
€6.18
€6.18
1.760%
0.108
1.760%
€14.65
28.11.25 / Tradegate
WKN: 896047 / Symbol: BCRX / Name: Biocryst Pharm / Stock / Biotechnology & Medical Research / Small Cap /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction
Biocryst Pharmaceuticals Stock
Biocryst Pharmaceuticals gained 1.760% today.
The stock is an absolute favorite of our community with 21 Buy predictions and no Sell predictions.
With a target price of 14 € there is potential for a 126.39% increase which would mean more than doubling the current price of 6.18 € for Biocryst Pharmaceuticals.
So far the community has only identified positive things for Biocryst Pharmaceuticals stock. The most positive votes were given for criterium "Worthwhile Investment for the next years".
Pros and Cons of Biocryst Pharmaceuticals in the next few years
Pros
?
B****
?
C******** o* t** e**********
?
G***** c******* t* c**********
Cons
?
S********** s********
?
M***** P*******
?
W********* I********* f** t** n*** y****
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Biocryst Pharmaceuticals vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Biocryst Pharmaceuticals | 1.760% | 2.249% | -1.403% | -12.950% | -15.496% | -47.893% | 44.587% |
| Ardelyx Inc. | -3.210% | 7.699% | 15.065% | -6.465% | 1.994% | 198.198% | 0.957% |
| Krystal Biotech | 0.480% | 2.688% | 16.119% | 1.639% | 24.244% | 148.816% | - |
| Evolus Inc | 1.710% | 5.405% | -0.847% | -53.571% | -44.286% | -18.182% | 85.479% |
Comments
BioCryst Pharmaceuticals (NASDAQ:BCRX) had its price target lowered by analysts at Needham & Company LLC from $20.00 to $18.00. They now have a "buy" rating on the stock.
Show more
Ratings data for BCRX provided by MarketBeat
BioCryst Pharmaceuticals (NASDAQ:BCRX) had its price target raised by analysts at Cantor Fitzgerald from $24.00 to $26.00. They now have an "overweight" rating on the stock.
Show more
Ratings data for BCRX provided by MarketBeat
BioCryst Pharmaceuticals (NASDAQ:BCRX) had its price target raised by analysts at Needham & Company LLC from $17.00 to $20.00. They now have a "buy" rating on the stock.
Show more
Ratings data for BCRX provided by MarketBeat